SEC Form 10-Q filed by Maze Therapeutics Inc.
$MAZE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/2/2025 | $30.00 | Buy | BTIG Research |
| 7/23/2025 | $34.00 | Buy | H.C. Wainwright |
| 7/8/2025 | $17.00 | Outperform | Wedbush |
S-1 - Maze Therapeutics, Inc. (0001842295) (Filer)
8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
144 - Maze Therapeutics, Inc. (0001842295) (Subject)
4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
3 - Maze Therapeutics, Inc. (0001842295) (Issuer)
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D., who will continue to serve on the Board. "I am honored to assume the role of Chairman of the Board at this pivotal moment for Maze Therapeutics," said Mr. Hoppenot. "With encouraging first-in-human data for MZE782, an oversubscribed $150 million private placement, and important clinical milestones ahead, including the advancement of M
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $150.0 million, before deducting placement agent fees and other expenses. The private placement includes participation from both new and existing investors including Frazier Life Sciences, Deep Track Capital, Driehaus Capital Management, Janus Henderson Investors, Logos Capital, TCGX, and Venr
Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid excretion demonstrated across all SAD and MAD cohorts, including up to a 42-fold increase in urinary phenylalanine (Phe) excretion, a well-validated biomarker for PKU and predictive for CKD Dose-dependent initial eGFR dip similar to SGLT2 inhibitors observed, supporting a potential kidney protective effect in CKD Well tolerated across all doses with an excellent safety profile and no serious adverse events observed Phase 2 trials in both PKU and CKD expected to initiate in 2026 Maze to hos
BTIG Research initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $30.00
H.C. Wainwright initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $34.00
Wedbush initiated coverage of Maze Therapeutics with a rating of Outperform and set a new price target of $17.00
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D., who will continue to serve on the Board. "I am honored to assume the role of Chairman of the Board at this pivotal moment for Maze Therapeutics," said Mr. Hoppenot. "With encouraging first-in-human data for MZE782, an oversubscribed $150 million private placement, and important clinical milestones ahead, including the advancement of M
Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid excretion demonstrated across all SAD and MAD cohorts, including up to a 42-fold increase in urinary phenylalanine (Phe) excretion, a well-validated biomarker for PKU and predictive for CKD Dose-dependent initial eGFR dip similar to SGLT2 inhibitors observed, supporting a potential kidney protective effect in CKD Well tolerated across all doses with an excellent safety profile and no serious adverse events observed Phase 2 trials in both PKU and CKD expected to initiate in 2026 Maze to hos